ISPOR 15TH ANNUAL EUROPEAN CONGRESS RESEARCH PRESENTATION AWARD RECIPIENTS

 

The ISPOR Best Research Podium and Poster Presentation Awards were established in 1998 to recognize the scientific merit of podium and poster presentations of the ISPOR Annual International Meetings, Annual European Congresses, and Asia-Pacific Conferences. At this year's European Congress, the ISPOR Awards Committee evaluated 56 podium presentations and over 1,000 poster presentations.

Evaluations of scientific merit were based upon the following criteria:

  • Background provides appropriate perspective/context for the subject
  • Objectives / research questions are clearly stated
  • Research design / methods / modeling is appropriate and transparent (scores on this will determine recipients in case of ties)
  • Data sources and/or sampling procedures are clear and appropriate
  • Data analyses are appropriate
  • Research objectives are met/addressed
  • Implications of findings are discussed
  • Factual information is kept separate from interpretations or implications
  • Abstract is presented in an unbiased manner
  • Clarity of presentation


THE RECIPIENTS  ARE: . . .

ISPOR Best Podium Research Presentation Awards

ISPOR Best Podium Research Presentation Awards

UT4 - HEALTH UTILITY SCORES IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: RESPONSE TO STIMULANT TREATMENT
Setyawan J1, Banaschewski T2, Hodgkins P3, Lecendreux M4, Johnson M5, Zuddas A6, Bloomfield R7, Coghill DR8
1Shire Development LLC, Wayne, PA, USA, 2University of Heidelberg, Mannheim, Germany, 3Shire Pharmaceuticals LLC, Wayne, PA, USA, 4CHU Hospital Robert-Debré, Paris, France, 5Queen Silvia Children's Hospital, Gothenburg, Sweden, 6University of Cagliari, Cagliari, Italy, 7Shire Pharmaceutical Development Ltd, Basingstoke, United Kingdom, 8Ninewells Hospital, Dundee, United Kingdom

NI2 - THE USE OF OFF-LABEL COMPARATORS IN NICE APPRAISALS – AN INDIRECT ENDORSEMENT?
Kusel J, Wong GK
Costello Medical Consulting Ltd, Cambridge, UK

CV3 - OUTCOMES AND COSTS OF CONCOMITANT AORTIC VALVE REPLACEMENTS ASSOCIATED WITH A NEW SUTURELESS AND COLLAPSED VALVE IN ITALY, FRANCE, GERMANY, AND THE UNITED KINGDOM
Pradelli L1, Zaniolo O1, Giardina S2, Ranucci M3
1AdRes HE&OR, Turin, Italy, 2Sorin Group, Saluggia, Italy, 3IRCSS Policlinico San Donato, San Donato Milanese, Italy

ISPOR Best New Investigator Podium Presentations Awards

CV2 - IS IT WORTH SPENDING ANY MONEY TO DEVELOP A BIOMARKER TEST TO OPTIMIZE STATIN TREATMENT FOR INDIVIDUALS WITH AN INTERMEDIATE CARDIOVASCULAR RISK?
Burgers LT1, Nauta ST2, Deckers JW2, Severens JL1, Redekop WK1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Erasmus Medical Center, Rotterdam, The Netherlands

NI3 - PATIENT ACCESS SCHEMES IN THE NEW NHS
Spoors J, Brown C, Johnson N, Rietveld A
RJW & Partners, Royston, Hertfordshire, UK
UT3 - ESTIMATING PREFERENCE-BASED INDEX FROM CANCER-SPECIFIC QUALITY OF LIFE MEASURES FOR USE IN COST-UTILITY-ANALYSIS
Teckle P, Peacock/Stuart S
Canadian Centre for Applied Research in Cancer Control, BC Cancer Agency, Vancouver, BC, Canada

 

ISPOR Best Student Podium Research Presentations Awards

QL4 - THE IMPACT OF DISEASE INFORMATION ON GENERAL PUBLIC PREFERENCES FOR HEALTH STATES: COMPARING LABELING, DISEASE-SPECIFIC, AND ADAPTATION INFORMATION
Butt T, Morris S, Orr S, Rubin G
University College London, London, UK

NI4 - ANALYSIS OF STAKEHOLDERS INVOLVED IN HTA DECISION MAKING PROCESS IN THE UNITED KINGDOM
Kalbasko A1, Andreykiv M2, Van Engen A3, Zorzi O2
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Quintiles, Hoofddorp, The Netherlands, 3Quintiles Global Consulting, Hoofddorp, Noord-Holland, The Netherlands

MO2 - IMPACT OF STRUCTURAL ASSUMPTIONS ON COST-EFFECTIVENESS OUTCOMES: TOWARDS A STANDARDIZED COST-EFFECTIVENESS MODEL FOR ADJUVANT BREAST CANCER THERAPIES
Frederix GW1, van Hasselt JG2, Schellens JH3, Hövels AM4, Huitema AD2, Raaijmakers JA5, Severens JL6
1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2Slotervaart Hospital & Netherlands Cancer Institute, Amsterdam, The Netherlands, 3Netherlands Cancer Institute & Utrecht University, Amsterdam, The Netherlands, 4Utrecht University, Utrecht, The Netherlands, 5Utrecht University & GlaxoSmithKline, Utrecht, The Netherlands, 6Erasmus University Rotterdam, Rotterdam, The Netherlands

ISPOR Best Poster Research Presentation Awards

ISPOR Best Research Presentations Poster Awards

PMD76 - THE EFFECT OF INSULIN PUMP THERAPY ON HEALTH STATUS AMONG THOSE WITH TYPE 1 DIABETES
Pignot M1, Eichmann F2, DiBonaventura MD3
1Kantar Health, München, Bavaria, Germany, 2Kantar Health GmbH, München, Germany, 3Kantar Health, New York, NY, USA

 

PMH2 - INTERIM RESULTS FROM THE "AUTOR" STUDY, A EUROPEAN OBSERVATIONAL STUDY IN PEDIATRIC PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER: PATIENT CHARACTERISTICS AND 1-YEAR COSTS
Haynes V1, Quail D2, Lorenzo M2, Deix C3, Anand H2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company, Surrey, UK, 3Eli Lilly and Company, Vienna, Austria

PSU7 - SEASONAL PERIODICITY OF SECONDARY HIP REPLACEMENT AFTER FEMORAL NECK FRACTURES WITH REDUCTION INTERNAL SCREW FIXATION AGED OVER 60
Sebestyén A1, Gajdácsi J2, Patzai B3, Molics B4, Varga S4, Sándor J5, Boncz I4
1 National Health Insurance Fund Administration, South-Transdanubian Regional Office, Pecs, Hungary, 2National Health Insurance Fund Administration, Budapest, Hungary, 3Department of Traumatology and Hand Surgery, University of Pecs, Hungary, 4Institute for Health Insurance, University of Pecs, Hungary, 5Department of Preventive Medicine, University of Debrecen, Hungary

ISPOR Best New Investigator Research Presentations Awards

PIN79 - HEPATITIS C VIRUS INFECTION INCREASES THE RISK OF ALZHEIMER'S DISEASES
Chiu WC1, Chen PC2
1Cathay General Hospital, Taipei, Taiwan, 2College of Public Health, National Taiwan University, Taipei, Taiwan

 

PIN84 - TRENDS IN PREVALENCE OF ANTIBACTERIAL DRUG USE AMONG DUTCH CHILDREN FROM 2005 UNTIL 2010
Joosten SGL1, Houweling LMA2, Penning FJA2
1Utrecht University, Utrecht, The Netherlands, 2PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands

PCN90 - COST EFFECTIVENESS ANALYSIS OF BENDAMUSTINE AS FIRST LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE NETHERLANDS
Vandekerckhove S1, Holtzer-Goor K2, Van Den Steen D1, van Megen Y3, Huijgens P4, Lamotte M1, Uyl- de Groot C5
1IMS Health, Vilvoorde, Belgium, 2iMTA, Rotterdam, Zuid Holland, The Netherlands, 3Mundipharma Pharmaceuticals, HOEVELAKEN, The Netherlands, 4VU University Medical Center, Amsterdam, The Netherlands, 5Erasmus University, Rotterdam, The Netherlands

ISPOR Best Student Poster Research Presentations Awards

PCN47- COST-OF-ILLNESS OF COMMON CANCER TYPES - RESULTS OF A HEALTH INSURANCE CLAIMS DATA ANALYSIS
Damm O
, Leppert F, Greiner W
School of Public Health, Bielefeld University, Bielefeld, Germany

PCN4 - DECISION-ANALYTIC MODEL FOR THE FIRST-LINE THERAPY OF CHRONIC MYELOID LEUKEMIA
Rochau U1, Sroczynski G2, Wolf D3, Schmidt S4, Conrads-Frank A2, Jahn B2, Saverno KR5, Brixner D6, Gastl G7, Radich J8, Siebert U9
1UMIT; Oncotyrol - Center for Personalized Cancer Medicine, Hall i.T.;Innsbruck, Tyrol, Austria, 2UMIT - University for Health Sciences, Medical Informatics and Technology; Oncotyrol - Center for Personalized Cancer Medicine, Hall i.T.;Innsbruck, Tyrol, Austria, 3University of Bonn, Medical University Innsbruck, Bonn/Innsbruck, Austria, 4Internal Medicine V, Hematology and Oncology, Medical University, Innsbruck, Austria, 5UMIT- Univ. for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; Univ. of Utah, Salt Lake City, USA, Hall i.T.;Innsbruck, Tyrol, Austria, 6University of Utah, College of Pharmacy, Salt Lake City, UT, USA, 7Medical University Innsbruck, Innsbruck, Austria, 8Fred Hutchinson Cancer Center, Seattle, WA, USA, 9UMIT/ Oncotyrol/ Harvard University, Hall i.T.;Innsbruck, Tyrol, Austria

PCN30 - TREATMENT PATTERNS AND OUTCOMES OF BREAST CANCER PATIENTS IN A PATIENT-CENTERED RETROSPECTIVE RESEARCH REGISTRY
Saokaew S1, Cai B1, Kuo KL2, Bauer H2, Albright F2, Brixner D2, Stenehjem D1
1University of Utah, Salt Lake City, UT, USA, 2University of Utah, College of Pharmacy, Salt Lake City, UT, USA

A special thanks goes to all the judges, the ISPOR Annual European Congress Research Presentation Awards Chairs as well as the ISPOR Awards Committee Chairs who volunteered their time and efforts in selecting the recipients.

 

 

Return to ISPOR Awards Index Page